$2.30
0.43%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US14757U1097
Symbol
CASI

CASI Pharmaceuticals Inc Stock price

$2.30
+0.35 17.95% 1M
+0.03 1.32% 6M
-0.53 18.73% YTD
-4.29 65.10% 1Y
-1.47 38.99% 3Y
-14.90 86.63% 5Y
-11.00 82.71% 10Y
-280.40 99.19% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.01 0.43%
ISIN
US14757U1097
Symbol
CASI
Industry

Key metrics

Basic
Market capitalization
$35.6m
Enterprise Value
$41.4m
Net debt
$5.8m
Cash
$12.7m
Shares outstanding
15.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.1 | 2.8
EV/Sales
1.3 | 3.2
EV/FCF
-
P/B
negative
Financial Health
Equity Ratio
3.5%
Return on Equity
-2,120.9%
ROCE
-568.8%
ROIC
-
Debt/Equity
-2.3
Financials (TTM | estimate)
Revenue
$31.4m | $12.8m
EBITDA
- | -
EBIT
$-40.4m | $-33.6m
Net Income
$-40.5m | $-32.7m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
8.4% | -55.3%
EBITDA
- | -
EBIT
-38.3% | 2.3%
Net Income
-32.8% | 16.7%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
56.6%
EBITDA
- | -
EBIT
-128.9%
Net
-129.1% | -256.5%
Free Cash Flow
-
More
EPS
$-2.6
FCF per Share
-
Short interest
2.6%
Employees
233
Rev per Employee
$120.0k
Show more

Is CASI Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

CASI Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a CASI Pharmaceuticals Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a CASI Pharmaceuticals Inc forecast:

Buy
86%
Hold
14%

Financial data from CASI Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
8% 8%
100%
- Direct Costs 14 14
13% 13%
43%
18 18
5% 5%
57%
- Selling and Administrative Expenses 45 45
10% 10%
143%
- Research and Development Expense 8.38 8.38
14% 14%
27%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -40 -40
38% 38%
-129%
Net Profit -40 -40
33% 33%
-129%

In millions USD.

Don't miss a Thing! We will send you all news about CASI Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CASI Pharmaceuticals Inc Stock News

Neutral
Accesswire
about 17 hours ago
- Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 2, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a...
Neutral
Accesswire
4 days ago
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today reported business and financial results for the quarter ended June 30, 2025 (the "second quarter"). "We are focused on adva...
Neutral
Accesswire
6 days ago
SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 3 ...
More CASI Pharmaceuticals Inc News

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.

Head office United States
CEO Wei He
Employees 233
Founded 1991
Website www.casipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today